ARTLW (Artelo Biosciences) Inventories, Inventories Adjustments: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARTLW Artelo Biosciences Inc ARTLW
32 GF Score
Price $0.01
! 2 Warning Signs
View Full Analysis

What is Artelo Biosciences Inventories, Inventories Adjustments?

Artelo Biosciences ARTLW 32 Inventories, Inventories Adjustments is $0.00 Mil as of Jun. 2026. GuruFocus rates ARTLW with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Artelo Biosciences's Inventories, Inventories Adjustments for the quarter that ended in Jun. 2026 was $0.00 Mil.

Artelo Biosciences Inventories, Inventories Adjustments Historical Data

* Premium members only.

The historical data trend for Artelo Biosciences's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artelo Biosciences Inventories, Inventories Adjustments Chart

Artelo Biosciences Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
Inventories, Inventories Adjustments
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Artelo Biosciences Quarterly Data
Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ARTLW
32GF Score
Artelo Biosciences Inc ARTLW
Inventories, Inventories Adjustments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artelo Biosciences Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.

What does a Inventories, Inventories Adjustments of $0.00 Mil mean?
Artelo Biosciences (ARTLW) has a Inventories, Inventories Adjustments of $0.00 Mil as of Jun. 2026. Inventories, Inventories Adjustments is certain charges made in the current period in inventory resulting from breakage, spoilage, etc. View historical data on Artelo Biosciences and its competitors.
Is Artelo Biosciences' Inventories, Inventories Adjustments too high?
Artelo Biosciences' current Inventories, Inventories Adjustments is $0.00 Mil. Overall, Artelo Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' Inventories, Inventories Adjustments compare to PPCB and CLDI?
Artelo Biosciences' Inventories, Inventories Adjustments of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Inventories Adjustments for a Biotechnology company?
A good Inventories, Inventories Adjustments depends on the Biotechnology industry context. However, Inventories, Inventories Adjustments should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Inventories Adjustments mean?
A high Inventories, Inventories Adjustments can signal that a stock is expensive relative to its fundamentals. Inventories, Inventories Adjustments is certain charges made in the current period in inventory resulting from breakage, spoilage, etc. View historical data on Artelo Biosciences and its competitors. Artelo Biosciences's current Inventories, Inventories Adjustments is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTLW) has a current Inventories, Inventories Adjustments of $0.00 Mil. The current Inventories, Inventories Adjustments is $0.00 Mil. Artelo Biosciences' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Inventories Adjustments calculated?
Inventories, Inventories Adjustments is calculated from a company's financial statements. For Artelo Biosciences (ARTLW), the current Inventories, Inventories Adjustments is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artelo Biosciences Business Description

Other Exchanges ARTL:USA
Address 505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
32GF Score

Get the complete analysis for ARTLW

Inventories, Inventories Adjustments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price